Global Therapeutics of Alzheimer's Disease Market 2023
The global Alzheimer's disease therapeutics market was valued at USD 3.52 billion in 2022 and is projected to reach USD 6.66 billion by 2029, with a CAGR of 9.2% from 2023 to 2029. Increasing prevalence of Alzheimer's disease worldwide and investments in therapeutic development are driving market growth. Alzheimer's disease is a progressive neurodegenerative disorder characterized by memory loss and cognitive impairment. Current treatments provide temporary symptom improvement, but there is a need for effective pharmacological approaches. Laboratory tests and brain-imaging technologies aid in diagnosis. The market primarily consists of symptomatic treatments, with seven approved medications. Clinical trials are in progress, with a focus on Phase II development. The approval of Aducanumab in 2021 and the introduction of novel therapies will contribute to market growth. The market is driven by the rising prevalence of Alzheimer's disease and significant R&D investments.
The report covers market size and growth, segmentation, competitive landscape, trends and strategies for global therapeutics of Alzheimer's disease market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.
Market Segmentation
The market is segmented based on various factors, including drug class, gender, age group, severity, and geography.
Drug class: ACE inhibitors, NMDA inhibitors, others
Gender: men, women
Age group: 65-74 years, 75-84 years, 85 years & above
Severity type: mild, moderate, severe
Geography: North America, Europe, APAC
ACE inhibitors are projected to have a significant share in the global Alzheimer's disease therapeutics market, but the fastest-growing segment is expected to be other classes of drugs. The recent approval of biologics like Aducanumab (Aduhelm) is anticipated to drive the global Alzheimer's disease therapeutics market in the future. In terms of gender, women are expected to contribute significantly due to their longer life expectancy and larger population affected by Alzheimer's disease. Among different age groups, those aged 85 years and above are expected to dominate the market, but the fastest-growing segment will be the population aged 65 years and above. Individuals with mild forms of the disease will hold a significant share in the global therapeutics market, while the fastest-growing segment will be individuals with moderate forms.
In the U.S., the incidence of Alzheimer's disease was reported to be 229,385 in 2021, and this number is predicted to increase substantially. The United States holds a dominant position in the global market due to factors such as affordability of healthcare, knowledge and awareness, and technological advancements. However, China is expected to experience faster growth with a high compound annual growth rate (CAGR) due to the rising geriatric population, increased awareness, and growing healthcare expenditure in the Asia-Pacific (APAC) region.
Competitive Landscape
The Alzheimer's Disease (AD) market is primarily dominated by symptomatic treatments, with seven approved medications available. Leading players in the global market include AbbVie Inc, Alzamend Neuro, Inc., Alzinova AB, Asceneuron SA, Biogen Inc, Biohaven, Ltd., BioVie Inc., Denali Therapeutics Inc., Eisai Co., Ltd., Eli Lilly and Company, GreenValley Inc., Johnson & Johnson, KeifeRx, LLC, NeuroKine Therapeutics LLC, Novartis AG, UCB SA, Vaccinex Inc, among others. These companies employ strategies such as collaborations, acquisitions, geographical expansion, research and development investments, and the development of novel drugs to compete in the market.
Recent Industry Developments
Biogen announced in April 2022 that the European Medicines Agency (EMA) withdrew the Marketing Authorization Application (MAA) for aducanumab due to insufficient data.
In March 2022, Corium, Inc. received FDA approval for Adlarity as a treatment for Alzheimer's disease patients with mild, moderate, or severe dementia.
In June 2021, Biogen obtained accelerated FDA approval for Aduhelm based on the results of Phase 3 clinical trials (EMERGE and ENGAGE) conducted on patients with early-stage Alzheimer's disease and confirmed amyloid pathology.
Scope of the Report
To analyze and forecast the market size of the global therapeutics of Alzheimer's disease market.
To classify and forecast the global therapeutics of Alzheimer's disease market based on drug class, gender, age group, severity type, geography.
To identify drivers and challenges for the global therapeutics of Alzheimer's disease market.
To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global therapeutics of Alzheimer's disease market.
To identify and analyze the profile of leading players operating in the global therapeutics of Alzheimer's disease market.
Why Choose This Report
Gain a reliable outlook of the global therapeutics of Alzheimer's disease market forecasts from 2023 to 2029 across scenarios.
Identify growth segments for investment.
Stay ahead of competitors through company profiles and market data.
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.
The report covers market size and growth, segmentation, competitive landscape, trends and strategies for global therapeutics of Alzheimer's disease market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.
Market Segmentation
The market is segmented based on various factors, including drug class, gender, age group, severity, and geography.
Drug class: ACE inhibitors, NMDA inhibitors, others
Gender: men, women
Age group: 65-74 years, 75-84 years, 85 years & above
Severity type: mild, moderate, severe
Geography: North America, Europe, APAC
ACE inhibitors are projected to have a significant share in the global Alzheimer's disease therapeutics market, but the fastest-growing segment is expected to be other classes of drugs. The recent approval of biologics like Aducanumab (Aduhelm) is anticipated to drive the global Alzheimer's disease therapeutics market in the future. In terms of gender, women are expected to contribute significantly due to their longer life expectancy and larger population affected by Alzheimer's disease. Among different age groups, those aged 85 years and above are expected to dominate the market, but the fastest-growing segment will be the population aged 65 years and above. Individuals with mild forms of the disease will hold a significant share in the global therapeutics market, while the fastest-growing segment will be individuals with moderate forms.
In the U.S., the incidence of Alzheimer's disease was reported to be 229,385 in 2021, and this number is predicted to increase substantially. The United States holds a dominant position in the global market due to factors such as affordability of healthcare, knowledge and awareness, and technological advancements. However, China is expected to experience faster growth with a high compound annual growth rate (CAGR) due to the rising geriatric population, increased awareness, and growing healthcare expenditure in the Asia-Pacific (APAC) region.
Competitive Landscape
The Alzheimer's Disease (AD) market is primarily dominated by symptomatic treatments, with seven approved medications available. Leading players in the global market include AbbVie Inc, Alzamend Neuro, Inc., Alzinova AB, Asceneuron SA, Biogen Inc, Biohaven, Ltd., BioVie Inc., Denali Therapeutics Inc., Eisai Co., Ltd., Eli Lilly and Company, GreenValley Inc., Johnson & Johnson, KeifeRx, LLC, NeuroKine Therapeutics LLC, Novartis AG, UCB SA, Vaccinex Inc, among others. These companies employ strategies such as collaborations, acquisitions, geographical expansion, research and development investments, and the development of novel drugs to compete in the market.
Recent Industry Developments
Biogen announced in April 2022 that the European Medicines Agency (EMA) withdrew the Marketing Authorization Application (MAA) for aducanumab due to insufficient data.
In March 2022, Corium, Inc. received FDA approval for Adlarity as a treatment for Alzheimer's disease patients with mild, moderate, or severe dementia.
In June 2021, Biogen obtained accelerated FDA approval for Aduhelm based on the results of Phase 3 clinical trials (EMERGE and ENGAGE) conducted on patients with early-stage Alzheimer's disease and confirmed amyloid pathology.
Scope of the Report
To analyze and forecast the market size of the global therapeutics of Alzheimer's disease market.
To classify and forecast the global therapeutics of Alzheimer's disease market based on drug class, gender, age group, severity type, geography.
To identify drivers and challenges for the global therapeutics of Alzheimer's disease market.
To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global therapeutics of Alzheimer's disease market.
To identify and analyze the profile of leading players operating in the global therapeutics of Alzheimer's disease market.
Why Choose This Report
Gain a reliable outlook of the global therapeutics of Alzheimer's disease market forecasts from 2023 to 2029 across scenarios.
Identify growth segments for investment.
Stay ahead of competitors through company profiles and market data.
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.
PART 1. INTRODUCTION
1.1 Description
1.2 Objectives of The Study
1.3 Market Segment
1.4 Years Considered for The Report
1.5 Currency
1.6 Key Target Audience
PART 2. RESEARCH METHODOLOGY
2.1 Primary Research
2.2 Secondary Research
PART 3. EXECUTIVE SUMMARY
PART 4. MARKET OVERVIEW
4.1 Introduction
4.2 Drivers
4.3 Restraints
PART 5. GLOBAL THERAPEUTICS OF ALZHEIMER'S DISEASE MARKET BY DRUG CLASS
5.1 ACE inhibitors
5.2 NMDA inhibitors
5.3 Others
PART 6. GLOBAL THERAPEUTICS OF ALZHEIMER'S DISEASE MARKET BY GENDER
6.1 Men
6.2 Women
PART 7. GLOBAL THERAPEUTICS OF ALZHEIMER'S DISEASE MARKET BY AGE GROUP
7.1 65-74 years
7.2 75-84 years
7.3 85 years & above
PART 8. GLOBAL THERAPEUTICS OF ALZHEIMER'S DISEASE MARKET BY SEVERITY TYPE
8.1 Mild
8.2 Moderate
8.3 Severe
PART 9. GLOBAL THERAPEUTICS OF ALZHEIMER'S DISEASE MARKET BY GEOGRAPHY
9.1 North America
9.2 Europe
9.3 APAC
PART 10. COMPANY PROFILES
10.1 AbbVie Inc
10.2 Alzamend Neuro, Inc.
10.3 Alzinova AB
10.4 Asceneuron SA
10.5 Biogen Inc
10.6 Biohaven, Ltd.
10.7 BioVie Inc.
10.8 Denali Therapeutics Inc.
10.9 Eisai Co., Ltd.
10.10 Eli Lilly and Company
10.11 GreenValley Inc.
10.12 Johnson & Johnson
10.13 KeifeRx, LLC
10.14 NeuroKine Therapeutics LLC
10.15 Novartis AG
10.16 UCB SA
10.17 Vaccinex Inc
DISCLAIMER
1.1 Description
1.2 Objectives of The Study
1.3 Market Segment
1.4 Years Considered for The Report
1.5 Currency
1.6 Key Target Audience
PART 2. RESEARCH METHODOLOGY
2.1 Primary Research
2.2 Secondary Research
PART 3. EXECUTIVE SUMMARY
PART 4. MARKET OVERVIEW
4.1 Introduction
4.2 Drivers
4.3 Restraints
PART 5. GLOBAL THERAPEUTICS OF ALZHEIMER'S DISEASE MARKET BY DRUG CLASS
5.1 ACE inhibitors
5.2 NMDA inhibitors
5.3 Others
PART 6. GLOBAL THERAPEUTICS OF ALZHEIMER'S DISEASE MARKET BY GENDER
6.1 Men
6.2 Women
PART 7. GLOBAL THERAPEUTICS OF ALZHEIMER'S DISEASE MARKET BY AGE GROUP
7.1 65-74 years
7.2 75-84 years
7.3 85 years & above
PART 8. GLOBAL THERAPEUTICS OF ALZHEIMER'S DISEASE MARKET BY SEVERITY TYPE
8.1 Mild
8.2 Moderate
8.3 Severe
PART 9. GLOBAL THERAPEUTICS OF ALZHEIMER'S DISEASE MARKET BY GEOGRAPHY
9.1 North America
9.2 Europe
9.3 APAC
PART 10. COMPANY PROFILES
10.1 AbbVie Inc
10.2 Alzamend Neuro, Inc.
10.3 Alzinova AB
10.4 Asceneuron SA
10.5 Biogen Inc
10.6 Biohaven, Ltd.
10.7 BioVie Inc.
10.8 Denali Therapeutics Inc.
10.9 Eisai Co., Ltd.
10.10 Eli Lilly and Company
10.11 GreenValley Inc.
10.12 Johnson & Johnson
10.13 KeifeRx, LLC
10.14 NeuroKine Therapeutics LLC
10.15 Novartis AG
10.16 UCB SA
10.17 Vaccinex Inc
DISCLAIMER
